JP2000510825A - 標的細胞への最適内在化をもたらす免疫リポソーム - Google Patents

標的細胞への最適内在化をもたらす免疫リポソーム

Info

Publication number
JP2000510825A
JP2000510825A JP09537121A JP53712197A JP2000510825A JP 2000510825 A JP2000510825 A JP 2000510825A JP 09537121 A JP09537121 A JP 09537121A JP 53712197 A JP53712197 A JP 53712197A JP 2000510825 A JP2000510825 A JP 2000510825A
Authority
JP
Japan
Prior art keywords
fab
polyethylene glycol
liposome
immunoliposome
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP09537121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510825A5 (enExample
Inventor
シー． ベンツ、クリストファー
パパハジョプーロス、デメトリス
ダブリュ． パーク、ジョン
ホン、キールン
カーポティン、ドミトリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2000510825A publication Critical patent/JP2000510825A/ja
Publication of JP2000510825A5 publication Critical patent/JP2000510825A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP09537121A 1996-04-18 1997-04-01 標的細胞への最適内在化をもたらす免疫リポソーム Pending JP2000510825A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/634,197 US6214388B1 (en) 1994-11-09 1996-04-18 Immunoliposomes that optimize internalization into target cells
US08/634,197 1996-04-18
PCT/US1997/005322 WO1997038731A1 (en) 1996-04-18 1997-04-01 Immunoliposomes that optimize internalization into target cells

Publications (2)

Publication Number Publication Date
JP2000510825A true JP2000510825A (ja) 2000-08-22
JP2000510825A5 JP2000510825A5 (enExample) 2004-12-02

Family

ID=24542800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09537121A Pending JP2000510825A (ja) 1996-04-18 1997-04-01 標的細胞への最適内在化をもたらす免疫リポソーム

Country Status (9)

Country Link
US (4) US6214388B1 (enExample)
EP (2) EP1655039A3 (enExample)
JP (1) JP2000510825A (enExample)
AT (1) ATE330637T1 (enExample)
AU (1) AU2601297A (enExample)
CA (1) CA2249352C (enExample)
DE (1) DE69736178T2 (enExample)
ES (1) ES2263175T3 (enExample)
WO (1) WO1997038731A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503424A (ja) * 1999-06-28 2003-01-28 プロクシマ コンセプツ リミテッド 結合補助体の非共有結合会合で形成されるエピトープ
JP2004529086A (ja) * 2000-11-09 2004-09-24 ネオファーム、インコーポレイティッド Ｓｎ−３８脂質複合体及び使用方法
JP2009520793A (ja) * 2005-12-22 2009-05-28 ドマンティス リミテッド 組成物
WO2010090222A1 (ja) * 2009-02-04 2010-08-12 国立大学法人大阪大学 Ｈｂ－ｅｇｆ結合性タンパク質複合体
JP2013543375A (ja) * 2010-09-03 2013-12-05 アカデミア シニカ 抗ｃ−ｍｅｔ抗体及びその使用方法
WO2023054243A1 (ja) * 2021-09-30 2023-04-06 日油株式会社 細胞指向性を有する脂質ナノ粒子

Families Citing this family (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
KR19990029749A (ko) * 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
EP0937456B1 (en) * 1998-02-23 2004-07-21 Cilag AG International Erythropoietin liposomal dispersion
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
WO2000009071A2 (en) * 1998-08-11 2000-02-24 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
WO2000020031A1 (en) * 1998-10-02 2000-04-13 Windy Hill Technology, Inc. Methods for identification, diagnosis, and treatment of breast cancer
WO2000054807A1 (en) * 1999-03-17 2000-09-21 Mitsubishi Chemical Corporation Ligand-bonded complex
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
EP1645292A1 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
AU2136501A (en) * 1999-12-10 2001-06-18 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
HUP0101480A2 (hu) * 2001-04-11 2004-01-28 István Horváth Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100965026B1 (ko) 2002-02-13 2010-06-21 이뮤놀로지 래보러토리스 인코포레이티드 미생물 감염증을 치료하기 위한 조성물 및 방법
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100470535B1 (ko) * 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP2006517917A (ja) * 2002-12-19 2006-08-03 アルザ・コーポレーシヨン 血管新生性の組織増殖の治療方法
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
WO2005037858A2 (en) * 2003-10-16 2005-04-28 University Of Massachusetts Template-directed assembly of receptor signaling complexes
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
PL2295073T3 (pl) 2003-11-17 2014-09-30 Genentech Inc Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
MX2007001064A (es) 2004-07-26 2007-04-12 Genentech Inc Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
EP1809246B1 (en) * 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
JP4990786B2 (ja) * 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
CN101437551A (zh) * 2004-11-19 2009-05-20 皇家飞利浦电子股份有限公司 用于分子成像的超声造影剂
ES2343746T3 (es) 2005-01-07 2010-08-09 Diadexus, Inc. Composiciones de anticuerpo ovr110 y metodos de uso.
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
BRPI0606557A2 (pt) * 2005-02-09 2009-06-30 Genentech Inc método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
EP1869076A2 (en) 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP1871424A2 (en) * 2005-04-22 2008-01-02 Alza Corporation Immunoliposome composition for targeting to a her2 cell receptor
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US20070014845A1 (en) * 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
US20070055199A1 (en) * 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ES2272178B1 (es) * 2005-09-19 2008-03-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
US20090155272A1 (en) * 2005-09-30 2009-06-18 Muschler John L Targeted pharmaceuticals and ligands
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
EP2023813A4 (en) * 2006-05-15 2013-03-13 Dmitri B Kirpotin MAGNETIC MICROPARTICLES COMPRISING ORGANIC SUBSTANCES
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US8541190B2 (en) * 2006-06-28 2013-09-24 Robert M. Weis Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
CA2657934C (en) 2006-07-19 2017-04-04 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
WO2008013918A2 (en) 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CA2690334C (en) * 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
WO2009020093A1 (ja) * 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2220116B1 (en) 2007-11-12 2012-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
ES2542308T3 (es) 2008-03-10 2015-08-04 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
MX2010012368A (es) 2008-05-16 2010-12-06 Genentech Inc Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5642673B2 (ja) 2008-07-10 2014-12-17 セリナ・セラピユーテイツクス・インコーポレーテツド 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
SG174891A1 (en) 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
CA2764729C (en) 2009-06-26 2019-04-02 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011076922A1 (en) 2009-12-23 2011-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
US20130202625A1 (en) * 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
EP3556396B1 (en) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012078695A2 (en) 2010-12-06 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
WO2012112730A2 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20130137688A (ko) 2011-03-31 2013-12-17 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
PH12014500925A1 (en) 2011-10-28 2014-06-09 Genentech Inc Therapeutic combinations and methods of treating melanoma
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US9493532B2 (en) 2011-12-15 2016-11-15 The University Of Chicago Compositions for cancer therapy using mutant light molecules with increased affinity to receptors
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102161271B1 (ko) * 2012-02-17 2020-09-29 셀젼 코퍼레이션 감열성 나노입자 제제 및 그의 제조 방법
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
NZ630990A (en) 2012-03-16 2016-04-29 Merck Patent Gmbh Aminoacid lipids
NZ631034A (en) 2012-03-16 2016-06-24 Merck Patent Gmbh Targeting aminoacid lipids
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
KR20190020838A (ko) 2012-04-27 2019-03-04 다이이찌 산쿄 가부시키가이샤 항-robo4 항체
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20150210758A1 (en) 2012-08-14 2015-07-30 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
KR102310697B1 (ko) 2012-11-20 2021-10-12 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
EP2925361A4 (en) 2012-12-03 2016-06-29 Merrimack Pharmaceuticals Inc COMBINATION THERAPY FOR THE TREATMENT OF HER2-POSITIVE CARCINOMA
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
EP2970449B1 (en) 2013-03-15 2019-09-25 Amgen Research (Munich) GmbH Single chain binding molecules comprising n-terminal abp
US11156608B2 (en) 2013-03-15 2021-10-26 The Trustees Of The University Of Pennsylvania Method for the site-specific covalent cross-linking of antibodies to surfaces
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
MX376808B (es) 2013-05-24 2025-03-07 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
MA38686A1 (fr) 2013-05-31 2017-10-31 Genentech Inc Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
US9931401B2 (en) 2013-10-08 2018-04-03 Daiichi Sankyo Company, Limited Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
WO2016022723A1 (en) 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
JP6751393B2 (ja) 2014-12-03 2020-09-02 ジェネンテック， インコーポレイテッド 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
KR20170086536A (ko) 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
EP3259597B2 (en) 2015-02-19 2026-04-15 Compugen Ltd. Pvrig polypeptides and methods of treatment
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
DK3283524T3 (da) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
AU2016260306B2 (en) 2015-05-12 2022-10-06 The Trustees Of The University Of Pennsylvania Compositions and methods for making antibody conjugates
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
ES2810700T3 (es) 2015-05-29 2021-03-09 Hoffmann La Roche Metilación del promotor de PD-L1 en cáncer
CA2991980A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
PL3337478T5 (pl) 2015-08-21 2026-05-04 Ipsen Biopharm Ltd. Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami
IL324412A (en) 2015-10-06 2026-01-01 Genentech Inc A method for treating multiple sclerosis
AU2016340153B2 (en) 2015-10-16 2022-06-02 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
PL3468997T3 (pl) 2016-06-08 2024-12-16 Xencor, Inc. Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP4372002A3 (en) 2016-09-14 2024-08-14 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
ES3039621T3 (en) 2016-12-22 2025-10-23 Daiichi Sankyo Co Ltd Anti-cd3 antibody, and molecule containing said antibody
AU2018214223B2 (en) 2017-02-02 2025-08-14 Amgen Inc. Low pH pharmaceutical composition comprising T cell engaging antibody constructs
RU2019128134A (ru) 2017-02-07 2021-03-09 Дайити Санкио Компани, Лимитед Антитело против gprc5d и молекула, содержащая антитело
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
EP3630830A1 (en) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
TW201927336A (zh) 2017-10-05 2019-07-16 日商第一三共股份有限公司 細胞毒性ｔ細胞耗竭用組成物
TWI827570B (zh) 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US20210115156A1 (en) 2018-04-13 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
CN112533946A (zh) * 2018-05-15 2021-03-19 旗舰创业创新六公司 病原体防治组合物及其用途
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
AU2020290573B2 (en) 2019-06-13 2026-01-29 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
MX2023003997A (es) 2020-10-06 2023-06-15 Xencor Inc Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
AU2022248779A1 (en) 2021-03-29 2023-09-28 Daiichi Sankyo Company, Limited Stable multispecific molecule and use thereof
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022245877A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
WO2022245859A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
NL2038054B1 (en) 2024-06-25 2026-01-15 Academisch Ziekenhuis Leiden A method for preparing liposomes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002069A1 (en) * 1981-12-10 1983-06-23 Univ California Thiol reactive liposomes
JPH03502885A (ja) * 1988-01-12 1991-07-04 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JPH04506518A (ja) * 1989-06-23 1992-11-12 ザ　リポソーム　カンパニー，インコーポレイテッド 標的化リポソーム及びリポソーム―蛋白質カップリング方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4155696A (en) * 1994-11-09 1996-06-06 Regents Of The University Of California, The Immunoliposomes that optimize internalization into target cells
JP3502885B2 (ja) 2000-01-12 2004-03-02 村田機械株式会社 画像拡大・縮小方法及びそれに用いるクロック生成回路

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002069A1 (en) * 1981-12-10 1983-06-23 Univ California Thiol reactive liposomes
JPH03502885A (ja) * 1988-01-12 1991-07-04 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JPH04506518A (ja) * 1989-06-23 1992-11-12 ザ　リポソーム　カンパニー，インコーポレイテッド 標的化リポソーム及びリポソーム―蛋白質カップリング方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6009021706, Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ ｃａｎｃｅｒ ｒｅｓｅａｒｃｈ ａｎｎｕａｌ ｍｅｅｔｉｎｇ, １９９４， Ｖｏｌ．３５， Ｎｏ．０, ｐａｇｅ ３８２ *
JPN6009021708, Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ, １９９５， Ｖｏｌ．９２， Ｎｏ．５, ｐａｇｅｓ １３２７−１３３１ *
JPN6009021710, Ｊ Ｂｉｏｌ． Ｃｈｅｍ．, １９９４， Ｖｏｌ．２６９， Ｎｏ．５, ｐａｇｅｓ ３１９８−３２０４ *
JPN7007000755, Ｂｉｏｃｈｉｍｉｃａ ｅｔ ｂｉｏｐｈｙｓｉｃａ ａｃｔａ, １９９５， Ｖｏｌ．１２３９, ｐａｇｅｓ １３３−１４４ *
JPN7007000757, Ｊｏｕｒｎａｌ ｏｆ ｌｉｏｓｏｍｅ ｒｅｓｅａｒｃｈ, １９９４， Ｖｏｌ．４， Ｎｏ．１, ｐａｇｅｓ １−２５ *
JPN7007000759, Ｔｒｅｎｄｓ ｉｎ ｐｈａｒｍａｃｏｌｏｇｉｃａｌ ｓｃｉｅｎｃｅｓ, １９９４， Ｖｏｌ．１５， Ｎｏ．１, ｐａｇｅｓ ２１５−２２０ *
JPN7007000760, Ｇｅｎｅｓ， ｏｎｃｏｇｅｎｅｓ， ａｎｄ ｈｏｒｍｏｎｅｓ： Ａｄｖａｎｃｅｓ ｉｎ ｃｅｌｌｕｌａｒ ａｎｄ ｍｏｌｅｃｕｌａｒ ｂｉｏｌｏｇｙ ｏｆ ｂｒｅａｓｔ ｃａｎｃｅｒ, １９９１, ｐａｇｅｓ １９３−２１１, Ｋｌｕｗｅｒ ａｃａｄｅｍｉｃ ｐｕｂｌｉｓｈｅｒｓ *
JPN7008000549, Ｇｅｎｅｓ，ｏｎｃｏｇｅｎｅｓ，ａｎｄ ｈｏｒｍｏｎｅｓ：Ａｄｖａｎｃｅｓ ｉｎ ｃｅｌｌｕｌａｒ ａｎｄ ｍｏｌｅｃｕｌａｒ ｂｉｏｌｏｇｙ ｏｆ ｂｒｅａｓｔ ｃａｎｃｅｒ, 1991, ｐａｇｅｓ １９３−２１１, Ｋｌｕｗｅｒ ａｃａｄｅｍｉｃ ｐｕｂｌｉｓｈｅｒｓ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503424A (ja) * 1999-06-28 2003-01-28 プロクシマ コンセプツ リミテッド 結合補助体の非共有結合会合で形成されるエピトープ
JP4754136B2 (ja) * 1999-06-28 2011-08-24 モザイク ディスカバリー リミテッド 結合補助体の非共有結合会合で形成されるエピトープ
JP2004529086A (ja) * 2000-11-09 2004-09-24 ネオファーム、インコーポレイティッド Ｓｎ−３８脂質複合体及び使用方法
JP2009520793A (ja) * 2005-12-22 2009-05-28 ドマンティス リミテッド 組成物
WO2010090222A1 (ja) * 2009-02-04 2010-08-12 国立大学法人大阪大学 Ｈｂ－ｅｇｆ結合性タンパク質複合体
JP5299922B2 (ja) * 2009-02-04 2013-09-25 国立大学法人大阪大学 Ｈｂ−ｅｇｆ結合性タンパク質複合体
JP2013543375A (ja) * 2010-09-03 2013-12-05 アカデミア シニカ 抗ｃ−ｍｅｔ抗体及びその使用方法
WO2023054243A1 (ja) * 2021-09-30 2023-04-06 日油株式会社 細胞指向性を有する脂質ナノ粒子

Also Published As

Publication number Publication date
ATE330637T1 (de) 2006-07-15
DE69736178D1 (de) 2006-08-03
US20010016196A1 (en) 2001-08-23
WO1997038731A1 (en) 1997-10-23
EP0912198A1 (en) 1999-05-06
US20100068255A1 (en) 2010-03-18
DE69736178T2 (de) 2007-05-24
EP0912198A4 (en) 2000-04-12
CA2249352A1 (en) 1997-10-23
US7135177B2 (en) 2006-11-14
ES2263175T3 (es) 2006-12-01
EP1655039A3 (en) 2010-01-27
EP0912198B1 (en) 2006-06-21
US6214388B1 (en) 2001-04-10
US20070031484A1 (en) 2007-02-08
US7871620B2 (en) 2011-01-18
US7507407B2 (en) 2009-03-24
EP1655039A2 (en) 2006-05-10
CA2249352C (en) 2012-06-05
AU2601297A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
US7135177B2 (en) Immunoliposomes that optimize internalization into target cells
AU2023263442B2 (en) Polyglutamated Antifolates And Uses Thereof
Park et al. Development of anti-p185HER2 immunoliposomes for cancer therapy.
US6943027B2 (en) Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
Lee et al. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro
US20040209366A1 (en) Methods for attaching proteins to lipidic microparticles with high efficiency
Bandekar et al. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo
US20080241161A1 (en) Remedy for mammary cancer
AU2008295666B2 (en) Improved liposomes and uses thereof
US20110027171A1 (en) Ph sensitive liposome composition
WO1996014864A1 (en) Immunoliposomes that optimize internalization into target cells
Shimizu et al. Liposomes Conjugated with a Pilot Molecule
US20100047334A1 (en) Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes
Bally et al. Liposome targeting following intravenous administration: defining expectations and a need for improved methodology
Perez-Soler et al. Liposomes as carriers of lipophilic antitumor agents
Tardi et al. The development of liposomes for enhanced delivery of chemotherapeutics to tumors
JPWO2006030602A1 (ja) 卵巣癌の診断および／または治療薬
HK1148937B (en) Improved liposomes and uses thereof
TW201018487A (en) Peptide ligand directed drug delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608